| 多细胞过继性免疫治疗治疗晚期恶性肿瘤的近期疗效及安全性分析 |
| |
| 引用本文： | 刘海波,宁 静,刘华胜,贺鹏程,段晓丽,张 梅.多细胞过继性免疫治疗治疗晚期恶性肿瘤的近期疗效及安全性分析[J].现代肿瘤医学,2019,0(7):1204-1207. |
| |
| 作者姓名： | 刘海波 宁 静 刘华胜 贺鹏程 段晓丽 张 梅 |
| |
| 作者单位： | 西安交通大学第一附属医院血液内科，陕西 西安 710061 |
| |
| 摘 要： | 目的:初步观察DC、CIK、γδT、CD3AK及NK细胞多细胞过继性免疫治疗对晚期恶性肿瘤患者的近期临床疗效及安全性分析。方法:对我院在2014年10月至2015年10月收治的162例次晚期恶性肿瘤患者进行多细胞过继性细胞免疫治疗，血细胞分离机单采自体外周血单个核细胞（peripheral blood mononuclear cells，PBMC)，体外培养扩增DC、CIK、γδT、CD3AK及NK细胞，采用FCM法检测各细胞表型，并按计划序贯回输给患者进行治疗。结果:69例（43%）患者临床症状有不同程度改善，尤其是精神、食欲及睡眠质量改善最为明显，安全性分析显示主要不良反应为发热，占15%，28例完成3疗程免疫治疗患者瘤体变化为部分缓解（partial remission，PR）2例，疾病稳定（stable disease，SD）16例，疾病控制率（disease control rate，DCR）为64%。结论:DC、CIK、γδT、CD3AK及NK细胞过继性免疫治疗对晚期恶性肿瘤安全有效，可明显改善其生活质量，具有一定的临床应用前景。
|
| 关 键 词： | 过继性细胞免疫治疗 恶性肿瘤 晚期 临床疗效 安全性 |
The short-term efficacy and safety of adoptive cellular immunotherapy of multi-cells for advanced cancer patients |
| |
| Liu Haibo,Ning Jing,Liu Huasheng,He Pengcheng,Duan Xiaoli,Zhang Mei.The short-term efficacy and safety of adoptive cellular immunotherapy of multi-cells for advanced cancer patients[J].Journal of Modern Oncology,2019,0(7):1204-1207. |
| |
| Authors: | Liu Haibo Ning Jing Liu Huasheng He Pengcheng Duan Xiaoli Zhang Mei |
| |
| Affiliation: | Department of Hematology，the First Affiliated Hospital of Xian Jiaotong University，Shaanxi Xi'an 710061，China. |
| |
| Abstract: | Objective:To investigate the short-term efficacy and satety of adoptive cellular immunotherapy of DC，CIK，γδT，CD3AK and NK cells for advanced cancer patients.Methods:162 patients with advanced cancer admitted to the our hospital from October 2014 to October 2015 were treated with the adoptive cellular immunotherapy.The DC，CIK，γδT，CD3AK and NK cells were generated and expanded from peripheral blood mononuclear cells(PBMC) obtained by hemapheresis，and the cells were transfused back to the patients after flow cytometry test.Results:The clinical symptoms of 69 patients(43%) were improved inordinately，and the spirit，the appetite and the sleep quality were improved most siginificantly.15% of all patients developed fever as major toxicity.28 patients finished 3 cycles of immunotherapy and 2 patients attained partial response(PR)，16 stable disease(SD) with an disease control rate（DCR） of 64%.Conclusion:The adoptive cellular immunotherapy of DC，CIK，γδT，CD3AK and NK cells is safe and effective and can improve the quality of life for advance cancer patients. |
| |
| Keywords: | adoptive cellular immunotherapy cancer advanced stage clinical efficacy safety |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
